MIT Professor Darrell Irvine describes a novel vaccine adjuvant: a nanoparticle that can help stimulate the immune system to generate a stronger response to a vaccine. An HIV vaccine with this adjuvant will be tested in clinical trials.
Researchers designed a new nanoparticle adjuvant that may be more potent than others now in use. Studies in mice showed it significantly improved antibody production following vaccination against HIV, diphtheria and influenza.